Evolving Market Trends In The Antiparasitic Drugs Industry: Innovative Chewable Antiparasitic Solutions Boost Pet Compliance in Veterinary Care

The Antiparasitic Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Antiparasitic Drugs Market Size During the Forecast Period?
The market size of antiparasitic drugs has seen significant growth in the past few years. It is projected to increase from a worth of $24.06 billion in 2024 to $25.75 billion in 2025, with a compound annual growth rate (CAGR) of 7.0%. The growth experienced in the historic period could be traced back to the widespread of parasitic infections, resistance against existing remedies, and worldwide health initiatives.

The market for antiparasitic drugs is projected to experience significant expansion in the upcoming years, with the size set to swell to $33.64 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. This growth during the projected period is due to factors such as the rise of new parasitic threats, climatic shifts, and the increase in vector-borne illnesses, as well as focus on global health safety and accessibility to healthcare. The major trends to expect in this period include progress in the development of drugs, specialized therapies, combined treatment methods, collaborations between public and private sectors, and the increasing use of telemedicine and remote diagnosis approaches.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12927

What Are the High-Growth Segments in the Antiparasitic Drugs Market?
The antiparasitic drugs market covered in this report is segmented -

1) By Product Type: Anthelmintics, Antiprotozoals, Ectoparasiticide, Other Products
2) By Treatment: Avermectins, Bezimidazoles, Pyrimidines, Organophosphates, Imidazolesthiazoles
3) By Route of Administration: Oral, Injectable, Topical
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Anthelmintics: Benzimidazoles, Ivermectin, Pyrantel Pamoate, Praziquantel
2) By Antiprotozoals: Metronidazole, Tinidazole, Nitazoxanide, Pentamidine
3) By Ectoparasiticides: Permethrin, Malathion, Lindane, Fipronil
4) By Other Products: Combination Antiparasitic Drugs, Novel Antiparasitic Agents

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12927&type=smp

What Key Drivers Are Expected to Influence Future Antiparasitic Drugs Market Growth?
A rise in occurrences of vector-borne diseases is projected to spur the development of the antiparasitic drugs market. Vector-borne diseases, which are infectious diseases transmitted by arthropods like mosquitoes, ticks, and flies, are spreading widely. Malaria, dengue, and yellow fever are examples of such diseases. Antiparasitic medications are crucial in curbing vector-borne diseases by eradicating the responsible parasites. Drugs like chloroquine, doxycycline, and atovaquone-proguanil are typically used for malaria treatment. The Centers for Disease Control and Prevention revealed in June 2024 that over 9.7 million dengue cases were reported in the Americas in the first half of 2024, more than twice the 4.6 million cases reported in 2023. Additionally, 1,498 cases were reported in Puerto Rico, with 745 cases recognized among U.S. travellers returning from the affected regions. Consequently, the escalating occurrence of vector-borne diseases augments the growth of the antiparasitic drugs market. Regarding the antiparasitic drugs market, its growth is predicted to be influenced by a high incidence of parasitic infections. Organisms invisible to the naked eye or larger organisms causing parasitic infections feed off their host, often causing harm or even disease. Antiparasitic medications play a crucial role in managing and controlling these infections. This helps improve health outcomes and decrease the overall impact of these diseases on affected communities and individuals. For example, according to Gov. UK, 31 cases of rickettsial infections were reported in EWNI in 2022, with 30 in England and 1 in Wales. Among these, 17 (55%) were confirmed cases, and 14 (45%) were considered probable. This high prevalence of parasitic infections bolsters the growth of the antiparasitic drug market.

Which Companies Hold the Largest Share Across Different Antiparasitic Drugs Market Segments?
Major companies operating in the antiparasitic drugs market are Pfizer Inc., Johnson & Johnson, Cadila Pharmaceuticals, Merck & Co.Inc., Bayer AG, Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim group, Zoetis Inc., Eisai Co. Ltd., Covetrus Inc., IDEXX Laboratories Inc., Dr. Reddy's Laboratories, Intas Pharmaceuticals Ltd., Alkem Laboratories Ltd., Ceva Sante Animale S.A., Elanco Animal Health Incorporated, Phibro Animal Health Corporation, Norbrook Laboratories Ltd., Mankind Pharma, Neogen Corporation, Bimeda Inc., Indoco Remedies Ltd., ECO Animal Health, Lincoln Pharmaceuticals Ltd., Laboratorios Calier.

What Trends Are Driving Growth in The Antiparasitic Drugs Market?
Leading firms in the antiparasitic drug market are concentrating on the development of creative products such as chewable veterinary goods to boost the ease of use and enhance pet adherence. Chewable veterinary goods are flavored, hassle-free tablets or treats that serve to deliver medication to animals. They improve pet adherence by making the treatment more enjoyable and less stressful. For instance, NexGard Spectra was launched by C.H. Boehringer Sohn AG and Co. KG, a pharmaceutical firm based in Germany, in April 2024 to offer comprehensive parasite control. NexGard SPECTRA is a tasty, soft chew that delivers all-inclusive internal and external parasite control for dogs, effectively combating fleas, ticks, heartworms, and various intestinal worms with just one monthly dosage. It displays quick action, exterminating fleas within four hours of being given and proving over 99% efficiency against a range of parasites not long after.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/antiparasitic-drugs-global-market-report

What Are the Emerging Geographies for The Antiparasitic Drugs Market Growth?
North America was the largest region in the antiparasitic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antiparasitic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Antiparasitic Drugs Market?
2. What is the CAGR expected in the Antiparasitic Drugs Market?
3. What Are the Key Innovations Transforming the Antiparasitic Drugs Industry?
4. Which Region Is Leading the Antiparasitic Drugs Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.